In the 1920s, Bayer—then called Schering AG—made a significant contribution to understanding the molecular structure of sex hormones and launched the world's first oestrogen preparation for menopause management. This firmly set Bayer as a pioneer in women’s healthcare and, in 1961, Bayer became the first company to launch a contraceptive pill in Europe, the combined oral contraceptive Anovlar® (norethisterone acetate/ethinylestradiol)1
More recent innovations include the introduction of Kyleena® (19.5 mg intrauterine delivery system levonorgestrel) a low-dose, levonorgestrel-releasing intrauterine delivery system which was launched in the UK in 2018.2
First European birth control pill, the combined oral contraceptive Anovlar® (norethisterone/ethinyl estradiol). Anovlar is no longer produced.
Progestogen-only pill (mini-pill)
First pill to treat premenstrual dysphoric disorder, a severe form of premenstrual syndrome, in the US for women who choose the contraceptive pill for birth control
Reporting adverse events and quality complaints
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 01182063500 or email: firstname.lastname@example.org
Further information is available on the “contact” tab at www.bayer.co.uk.